269 related articles for article (PubMed ID: 31903277)
41. Recent Advances in Castleman Disease.
Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
[TBL] [Abstract][Full Text] [Related]
42. [Analysis of the clinicopathologic features as well as diagnosis and treatment of 59 patients with Castleman disease].
Wang J; Liang LJ; Wang YM; Mei ZY; Liu YZ; Liu LN; Fang BJ; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):666-670. PubMed ID: 32942821
[No Abstract] [Full Text] [Related]
43. Clinicopathological Profile of Castleman's Disease in Indian Population: Experience From a Tertiary Care Center.
Singh A; Purkait S; Mallick S; Ramteke P; Das CK; Gogia A; Sharma MC; Kumar L
Indian J Hematol Blood Transfus; 2020 Apr; 36(2):254-259. PubMed ID: 32425374
[TBL] [Abstract][Full Text] [Related]
44. Transcriptome and unique cytokine microenvironment of Castleman disease.
Wing A; Xu J; Meng W; Rosenfeld AM; Li EY; Wertheim G; Paessler M; Bagg A; Frank D; Tan K; Teachey DT; Lim MS; Prak EL; Fajgenbaum DC; Pillai V
Mod Pathol; 2022 Apr; 35(4):451-461. PubMed ID: 34686774
[TBL] [Abstract][Full Text] [Related]
45. Emerging role of 18F-FDG PET/CT in Castleman disease: a review.
Koa B; Borja AJ; Aly M; Padmanabhan S; Tran J; Zhang V; Rojulpote C; Pierson SK; Tamakloe MA; Khor JS; Werner TJ; Fajgenbaum DC; Alavi A; Revheim ME
Insights Imaging; 2021 Mar; 12(1):35. PubMed ID: 33709329
[TBL] [Abstract][Full Text] [Related]
46. Diagnosis and management of Castleman disease.
Soumerai JD; Sohani AR; Abramson JS
Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
[TBL] [Abstract][Full Text] [Related]
47. Are Patients with HHV-8 Associated Castleman Disease Successfully Treated with Rituximab at Risk of Subsequently Developing HHV-8 Negative (Idiopathic) Castleman Disease?
Ha G; Kwong K; Tanaka B; Nishimura Y; Chong C
Eur J Case Rep Intern Med; 2023; 10(7):003904. PubMed ID: 37455698
[TBL] [Abstract][Full Text] [Related]
48. Unicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
[TBL] [Abstract][Full Text] [Related]
49. UCD with MCD-like inflammatory state: surgical excision is highly effective.
Zhang MY; Jia MN; Chen J; Feng J; Cao XX; Zhou DB; Fajgenbaum DC; Zhang L; Li J
Blood Adv; 2021 Jan; 5(1):122-128. PubMed ID: 33570636
[TBL] [Abstract][Full Text] [Related]
50. [Castleman disease. Histopathological and immunohistochemical analysis of 39 cases].
Sevilla-Lizcano DB; Frias-Soria CL; Ortiz-Hidalgo C
Gac Med Mex; 2017; 153(5):550-558. PubMed ID: 29099112
[TBL] [Abstract][Full Text] [Related]
51. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
52. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.
Zhou QY
World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591
[TBL] [Abstract][Full Text] [Related]
53. Castleman disease presenting in the neck: report of a case and review of the literature.
Puram SV; Hasserjian RP; Faquin WC; Lin HW; Rocco JW
Am J Otolaryngol; 2013; 34(3):239-44. PubMed ID: 23375540
[TBL] [Abstract][Full Text] [Related]
54. Clinical characteristics and prognosis of patients with Castleman disease in a Chinese hospital: paraneoplastic pemphigus is an independent risk factor.
Hua Y; Liang C; Yang J; Wang L; Xu A; Xi L; Wang S; Wang Z
Am J Transl Res; 2022; 14(2):1051-1059. PubMed ID: 35273707
[TBL] [Abstract][Full Text] [Related]
55. Cutaneous involvement as initial presentation of multicentric plasmacytic Castleman disease.
Chen H; Ba W; Chen H; Yang H
J Cutan Pathol; 2021 May; 48(5):701-705. PubMed ID: 33469928
[TBL] [Abstract][Full Text] [Related]
56. The Potential Clinical Benefit of Tocilizumab Therapy for Patients with HHV-8-infected AIDS-related Multicentric Castleman Disease: A Case Report and Literature Review.
Barlingay G; Findakly D; Hartmann C; Amar S
Cureus; 2020 Apr; 12(4):e7589. PubMed ID: 32399323
[TBL] [Abstract][Full Text] [Related]
57. Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital.
González-García A; Patier de la Peña JL; García-Cosio M; Sarhane Y; Sánchez Díaz C; Barbolla Díaz I; López Rodríguez M; Moreno MÁ; Villarubia J; Manzano L
Leuk Lymphoma; 2019 Dec; 60(14):3442-3448. PubMed ID: 31305183
[TBL] [Abstract][Full Text] [Related]
58. Clinical and experimental study of Castleman disease in children.
Zhang J; Li C; Lv L; Yang C; Kong XR; Zhu J; Zhang Y; Wang S
Pediatr Blood Cancer; 2015 Jan; 62(1):109-14. PubMed ID: 25213773
[TBL] [Abstract][Full Text] [Related]
59. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
[TBL] [Abstract][Full Text] [Related]
60. A retrospective study of 34 patients with unicentric and multicentric Castleman's disease: Experience from a single institution.
Jiang JP; Shen XF; Du JF; Guan WX
Oncol Lett; 2018 Feb; 15(2):2407-2412. PubMed ID: 29434951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
